Doxorubicin as a Potential Treatment Option in Canine Mammary Tumors

Area of Science:

• Veterinary Oncology
• Cancer Cell Biology
• Pharmacology

Background:

• Canine mammary tumors (CMTs) are a significant health concern in female dogs, necessitating advanced therapeutic strategies beyond surgery.
• Doxorubicin, a chemotherapy agent, has demonstrated efficacy in human cancers by modulating key cellular processes including apoptosis, autophagy, cell cycle, invasion, and epithelial-to-mesenchymal transition (EMT).

Purpose of the Study:

• To investigate the effects of Doxorubicin on canine mammary cancer cell lines.
• To evaluate Doxorubicin's impact on cell proliferation and EMT-related gene expression in canine models.

Main Methods:

• Treatment of two distinct canine mammary cancer cell lines (P114 and CMT-U27) with Doxorubicin.
• Assessment of Doxorubicin's effects on cell proliferation rates.
• Analysis of the expression of genes associated with the epithelial-to-mesenchymal transition (EMT).

Main Results:

• Doxorubicin treatment significantly inhibited cell proliferation in both P114 and CMT-U27 canine mammary cancer cell lines.
• Doxorubicin administration led to notable alterations in the expression of EMT-related genes within the studied cell lines.

Conclusions:

• Doxorubicin demonstrates anti-proliferative effects on canine mammary cancer cells in vitro.
• The drug influences phenotypic characteristics by altering EMT-related gene expression, suggesting a potential therapeutic role.
• These findings provide crucial insights into the relationship between Doxorubicin, phenotypic modulation, and proliferation in canine mammary tumor models.